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disease management program, signiﬁcantly lower costs were
noted during Year 1 which continued and expanded through
Year 2 relative to matched comparators. Beyond claims analyses,
however, incremental cost-effectiveness of disease management
programs must also consider program-speciﬁc expenditures and
clinical outcome measures.
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OBJECTIVE: To examine whether physicians’ practice specialties
are associated with the types of anti-diabetic treatments for
patients with type 2 diabetes (T2D). METHODS: A retrospective
study design was used based. All T2D patients’ (N = 1,819,323)
medication histories in a 12 month period were examined and
classiﬁed into 9 treatment types (no anti-diabetic medication, oral
anti-diabetic medication (OAD), basal insulin only, prandial
insulin only, basal insulin with OAD, prandial insulin with OAD,
basal/prandial insulin, basal/prandial insulin(including premixed
insulins) with OAD, other insulin regimens). Physicians practice
specialties were classiﬁed into ﬁve categories (family medicine,
internal medicine, other primary care specialists, endocrino-
logists, other specialties). A two-way contingency table was
created with Chi-square test and Fisher’s exact test to examine the
possible association between physicians’ practice specialty and the
types of anti-diabetic treatments they prescribed.RESULTS: Both
the Chi-square test and the Fisher’s exact test had p < 0.0001,
indicating that physicians’ practice specialty and their patients’
anti-diabetic treatment choices were statistically signiﬁcantly
associated. The contingency table suggests that the percent of
patients receiving no anti-diabetic medications varied across spe-
cialties from 36.0% in patients who visited an endocrinologist to
49% and 52% in patients who visited a family medicine physician
or internist, respectively. The percent of patients receiving OAD
only varied across specialties from 33.1% in patients who visited
an endocrinologist to 46.8% in patients who saw a family medi-
cine physician, and 43.6% in patients under the care of an
internist. And the percent of patients receiving insulin as part of
their regimen varied across specialties from4.12% in patientswho
visited a family medicine physician to 12.3% in patients who
visited an endocrinologist. CONCLUSION: Physicians’ practice
specialty is strongly associated with anti-diabetic medications
prescribed for patients with T2D. Further research to examine
outcomes differences across physician specialties is needed.
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OBJECTIVE: In the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial (a 10-year, 70 site study of diabetes
treatments), four health state preference measures (HSPMs),
which vary in theoretical constructs, are being collected. Our
objectives were to compare baseline values of the feeling
thermometer (FT), the Health Utilities Index, Mark 2 and Mark
3 (HUI-2 and HUI-3), and the SF-6D, derived from the Short
Form 36 and to explore associations between each HSPM
and 29 baseline clinical and demographic characteristics.
METHODS: Participants (n = 2053) were randomly selected for
the cost effectiveness sub-study of ACCORD. To compare the
HSPMs, we determined correlations between the measures, by
overall score and within each quartile range. We used multivari-
ate regression models to identify relationships between clinical
and demographic characteristics for each HSPM. RESULTS:
The mean  standard deviation HSPMs were: FT = 0.756 
0.167, HUI-2 = 0.823  0.146, HUI-3 = 0.712  0.260, and
SF-6D = 0.684  0.085. Although all 4 measures were signiﬁ-
cantly correlated with each other (Spearman r = 0.29–0.84
(p < 0.0001); relationships were weaker between the FT and the
other measures (0.29–0.38) and strongest between the two HUI
measures (0.84). By quartiles of HSPM, signiﬁcant correlations
were more common at the lowest quartile. In multivariate
regression analyses, we identiﬁed signiﬁcant associations
(p < 0.01) between HSPM values and age (positive), gender
(lower for females), years of education (positive), and race
(lower for non-white). Clinical characteristics inversely associ-
ated with HSPMs were duration of diabetes, current smoking,
secondary cardiovascular disease, total cholesterol, waist cir-
cumference, and body mass index. Number of medications
(blood pressure, glycemic, or lipid) were not signiﬁcantly
associated with HSPMs. Glycosylated hemoglobin values were
inversely related to FT only. CONCLUSION: Our results
suggest that the four instruments,result in different HSPM
values. Relationships with clinical and demographic variables
vary by HSPM. Therefore, results of cost-effectiveness results
may be impacted by the speciﬁc HSPM applied.
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OBJECTIVE: The aim of this study was to collect comparable
and reliable data about consumption of drugs for treatment of
diabetes mellitus in Slovakia during the period 1996–2006.
METHODS: Data of wholesalers (following ATC/DDD), who
are legally obliged provide this information to the Slovak Insti-
tute for Drug Control, was used for the analysis. The results
were expressed in the numbers of the packages, ﬁnance units (€)
and deﬁned daily doses per 1000 inhabitants per day (DID).
RESULTS: The collected data shows a moderate increases in the
antidiabetic’s consumption from 1996 to 2006 in term of DID (in
1996 (27.03), in 2001 (32.62) and in 2006 (37.90). A slight
increase in A10AB group (Insulins and analogues, fast-acting) in
1996 (1.88), in 2001 (2.79) and in 2006 (4.64), a slight decrease
in A10AC group (Insulins and analogues, intermediate-acting) in
1996 (4.25), in 2001 (3.74) and in 2006 (3.35), a moderate
increase in A10AD (Insulins and analogues, intermediate-acting
combin.) in 1996 (0.51), in 2001 (2.36) and in 2006 (3.25), a
steady increase in A10AE (Insulins and analogues, long-acting) in
2001 (0.03) and in 2006 (0.89), a dramatic increase in A10BA
(Biguanides) in 1996 (4.45), in 2001 (5.75) and in 2006 (9.46),
relatively stable consumption in A10BB (Sulfonamides, urea
derivatives) in 1996 (15.33), in 2001 (17.19) and in 2006 (14.76)
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